The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study
ConditionTakotsubo Cardiomyopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCedars-Sinai Medical Center
About this trial
The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.
Eligibility criteria
Qualifiers
Have received a diagnosis of Takotsubo from their physician and consent to enroll
Submit full medical records needed for Takotsubo adjudication
Disqualifiers
Younger than 18 years
Unable to provide informed consent
Unable to provide the necessary documentation needed for screening purposes
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov